ASCO 2015 publishes Prolong Pharmaceuticals’ e-Abstract of the Potential use of PEG – HbCO

ASCO 2015 has published Prolong Pharmaceuticals, LLC’s e-Abstract of the Potential use of PEG – HbCO in severe anemia in 5 eIND patients. The e-Abstract was developed by Prolong Pharmaceutical team members Deven V. Parmar, Hemant K. Misra, John B. Berryman, and Abraham Abuchowski

Patients who are unable to receive blood transfusions as a result of severe anemia are at risk of morbidity. Hhemolytic reactions and religious idealogies are the most common causes of patients choosing to abstain from blood transfusions. Pegylated bovine carboxyhemoglobin (PEG-HbCO) has been used in five patients who have declined blood transfusions, including a patient who developed a severe hemolytic reaction following stem cell transplantation.

Five patients with hemoglobin (Hb) levels below 3.5 g/dL were successfully treated by administering repeated doses of PEG-HbCO. The doses given ranged from a low of 1 unit/day for 2 to 4 days, to a high of up to 8 units for 9 days. A unit of PEG-HbCO is defined as 500 mL (40 mg/mL). No adverse events associated with PEG-HbCO were reported. The patients’ ages varied, ranging from 19 to 61 years old, and their diagnoses included AML, hemolytic reaction, acute chest syndrome and sickle cell crisis.

The investigators observed clinical improvements in their patients following administration of PEG-HbCO, regardless of persistent low Hb levels. Patients also reported an improved sense of well-being. The number and size of allowed blood draws were restricted; therefore analysis of clinical chemistries was limited. One patient exhibited a increased cerebral oximetry, while another patient exhibited cerebral blood flow improvement, measured by TCD. Patients exhibited increased responsiveness and self-reported comfort, who had previously experienced neurological deficit and fatigue, within close temporal association with PEG-HbCO treatment. Drawing from the improved clinical status of these patients, one can infer that PEG-HbCO has potential use for patients with severe anemia who are unable to receive blood transfusions.